華通醫藥(002758.SZ)延期回覆《中國證監會行政許可項目審查一次反饋意見通知書》
格隆匯1月10日丨華通醫藥(002758.SZ)公佈,公司於2019年12月3日收到中國證監會出具的《中國證監會行政許可項目審查一次反饋意見通知書》(192726號)。中國證監會依法對公司提交的《浙江華通醫藥股份有限公司上市公司發行股份購買資產核准》行政許可申請材料進行了審查,需要公司就有關問題作出書面説明和解釋,並在30個工作日內向中國證監會行政許可受理部門提交書面回覆意見。
公司收到反饋意見後,立即會同相關中介機構就反饋意見中提出的有關問題進行了認真分析,積極推進反饋意見的回覆工作。由於反饋意見中涉及的有關問題仍需公司及中介機構進一步核查落實,預計無法在規定的時間內向中國證監會提交反饋意見的書面回覆。本着認真落實反饋意見的原則,為穩妥做好反饋意見的回覆及相關申報材料的補充完善工作,經與中介機構審慎協商,公司向中國證監會提交了延期回覆申請,申請延期不超過30個工作日。待相關文件準備完成後,公司將會同相關中介機構及時向中國證監會提交反饋意見回覆材料,並及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.